You are here

JPMHC 2019

J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis

Fierce Pharma

Wed, 01/9/19 - 12:56 pm

Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma

BioSpace

Wed, 01/9/19 - 09:40 am

SAGE Therapeutics

Bristol-Myers Squibb

Gilead Sciences

Here's Why Nektar Therapeutics Surged Today

Motley Fool

Tue, 01/8/19 - 07:12 pm

Nektar Therapeutics

JPM: Why hasn't Merck been making deals? It's not for lack of trying, CEO says

Fierce Pharma

Tue, 01/8/19 - 10:37 am

7 Things to Expect for Gilead Sciences in 2019

Motley Fool

Tue, 01/8/19 - 09:12 am

Gilead Sciences

JPM: Years into troubled launch, vaccine head says Sanofi's learned some Dengvaxia lessons

Fierce Pharma

Tue, 01/8/19 - 11:24 am

3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't

Motley Fool

Tue, 01/8/19 - 12:43 am

Bristol-Myers Squibb

3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear

Motley Fool

Tue, 01/8/19 - 12:40 am

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises

Fierce Pharma

Tue, 01/8/19 - 12:38 am

A New Day, a New Vant. Roivant Launches Alyvant Ahead of J.P. Morgan 2019

BioSpace

Mon, 01/7/19 - 12:24 pm

Vivek Ramaswamy

The Week Ahead In Biotech: Conferences, Clinical Trials

Yahoo/Benzinga

Sun, 01/6/19 - 01:55 pm

Axsome Therapeutics

Miragen Therapeutics

After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That

Forbes

Sat, 01/5/19 - 03:04 pm

Bristol-Myers Squibb

A year after ‘the Michaels,’ more women will take the JPM stage — but 90 percent of presenters are still male

Stat

Sat, 01/5/19 - 01:43 pm

gender diversity

Pages